TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03804424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples for serum stability
Description: -3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples for serum stability
Description: -3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples for metabolite analysis
Description: -Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples for metabolite analysis
Description: -Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: -Cohort 1 only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Cohort 2 only and only if there hasn't been a recent biopsy of disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: -A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: -A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: -All PET imaging will be performed as PET/MR or PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: -All PET imaging will be performed as PET/MR or PET/CT
Study: NCT03681990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep
Description: Apply topically to intact skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep
Description: Apply topically to intact skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep
Description: Apply topically to intact skin
Study: NCT05861492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Differential Diagnosis Aid
Description: The Fatigue Differential Diagnosis Aid is a systematic questionnaire covering the symptoms and signs of fatigue and the collateral clinical data trying to facilitate the diagnostic process in the care of patient with symptoms of fatigue.
Study: NCT04252859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluoroestradiol (FES) PET/CT
Description: \[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
Study: NCT05729945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visiting
Description: The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
Study: NCT04577833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (AA)
Description: Abiraterone Acetate will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (AA)
Description: Abiraterone Acetate will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (AA)
Description: Abiraterone Acetate will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (AA)
Description: Abiraterone Acetate will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally.
Study: NCT02276885

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBI Radiotherapy 6 Gy
Description: Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBI Radiotherapy 8 Gy
Description: Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
Study: NCT03754205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microablative Fractional CO2 laser
Description: 3 therapies intravaginally administered will be applied at monthly intervals

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microablative Fractional CO2 laser
Description: 3 therapies intravaginally administered will be applied at monthly intervals
Study: NCT00793156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine HCl 2.5 µg
Description: Daily dose of 2.5 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine HCl 5.0 µg
Description: Daily dose of 5.0 µg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily dose
Study: NCT02889666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin
Description: Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Oxaliplatin
Description: Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Carboplatin
Description: Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
Study: NCT02727686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Load (WL) Post-Operative Day 1
Description: Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
Study: NCT04041050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Capsule; Oral
Study: NCT04130139

Intervention type: OTHER
Intervention: oocyte pick up simulator
Description: oocyte pick up simulation
Study: NCT02048748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight and blood pressure device
Description: Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home telemonitoring device
Description: An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
Study: NCT04096612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital decompression combined with MPT
Description: Orbital decompression combined with MPT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital decompression combined with MPT
Description: Orbital decompression combined with MPT
Study: NCT02320747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Study: NCT01935856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study: NCT01410942

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
Study: NCT03224416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
Study: NCT04404088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04237753

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Video Connect
Description: Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyHealtheBladder
Description: Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
Study: NCT02895854

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated RT 5 x 7,25 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LDR-brachytherapy with I125 seeds
Study: NCT01703988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Single IT injection for each dose
Study: NCT02446262

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Instructions
Description: In sub-study 1, half the participants are instructed about outcomes, half learn through experience.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Instructions
Description: In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
Study: NCT03224416

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alcohol Administration
Description: In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Alcohol Administration
Description: In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
Study: NCT01075646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h
Study: NCT02807506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Service Robot
Description: The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
Study: NCT02446262

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention
Description: In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Thermal Pain
Description: In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Thermal Pain
Description: In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Thermal Pain
Description: In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Placebo instructions
Description: In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
Study: NCT03496168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules
Study: NCT03287453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01845974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermoCool® SF NAV Catheter
Description: The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoCool® catheter
Description: The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
Study: NCT02807506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Service Robot
Description: The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.
Study: NCT03028337

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spine Radiosurgery
Description: Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction).
Study: NCT02807506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.
Study: NCT02735512

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples
Study: NCT03028337

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Spine Radiosurgery
Description: Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up.
Study: NCT02285114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: F/TAF tablets administered orally once daily